UB Paderborn / Katalog / Suche / in CDI

Synthesis of the Oxygenated Pactamycin Core

Organic letters, 2007-03, Vol.9 (7), p.1359-1362

2007

Link zum Volltext

Verfügbarkeit prüfen

CXCR2 receptor antagonists: a medicinal chemistry perspective

Current topics in medicinal chemistry, 2014-09, Vol.14 (13), p.1590

2014

Link zum Volltext

Verfügbarkeit prüfen

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

Bioorganic & medicinal chemistry letters, 2007-07, Vol.17 (13), p.3778-3783

2007

Link zum Volltext

Verfügbarkeit prüfen

Substituted dibenzo[c, h]cinnolines: Topoisomerase I-targeting anticancer agents

Bioorganic & medicinal chemistry, 2003-04, Vol.11 (7), p.1475-1491

2003

Link zum Volltext

Verfügbarkeit prüfen

Chemoselective Peptide Modification via Photocatalytic Tryptophan β‑Position Conjugation

Journal of the American Chemical Society, 2018-06, Vol.140 (22), p.6797-6800

2018

Link zum Volltext

Verfügbarkeit prüfen

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (15), p.4446-4449

2009

Link zum Volltext

Verfügbarkeit prüfen

3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists

Bioorganic & medicinal chemistry, 2008, Vol.18 (1), p.228-231

2008

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and structure–activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (4), p.1318-1322

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

Bioorganic & medicinal chemistry letters, 2020-07, Vol.30 (13), p.127197-127197, Article 127197

2020

Link zum Volltext

Verfügbarkeit prüfen

CXCR2 modulators: a patent review (2009 - 2013)

Expert opinion on therapeutic patents, 2014-05, Vol.24 (5), p.519-534

2014

Link zum Volltext

Verfügbarkeit prüfen

Identification of Oxidation Products of (−)-Epigallocatechin Gallate and (−)-Epigallocatechin with H2O2

Journal of agricultural and food chemistry, 2000-04, Vol.48 (4), p.979-981

2000

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity

Journal of medicinal chemistry, 2021-04, Vol.64 (8), p.4709-4729

2021

Link zum Volltext

Verfügbarkeit prüfen

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes

Bioorganic & medicinal chemistry letters, 2020-09, Vol.30 (17), p.127390-127390, Article 127390

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2‑Substituted Benzamide Zinc Binding Group

ACS medicinal chemistry letters, 2020-12, Vol.11 (12), p.2476-2483

2020

Link zum Volltext

Verfügbarkeit prüfen

A new synthesis of 3,4-disubstituted 1,2,5-thiadiazoles

Tetrahedron letters, 2007-07, Vol.48 (30), p.5279-5282

2007

Link zum Volltext

Verfügbarkeit prüfen

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV‑1 Protein for Clearance

ACS medicinal chemistry letters, 2020-07, Vol.11 (7), p.1476-1483

2020

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of HDAC Inhibitor Libraries via Microscale Workflow

ACS medicinal chemistry letters, 2021-03, Vol.12 (3), p.337-342

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery of novel BTK inhibitors with carboxylic acids

Bioorganic & medicinal chemistry letters, 2017-03, Vol.27 (6), p.1471-1477

2017

Link zum Volltext

Verfügbarkeit prüfen

Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists

Bioorganic & medicinal chemistry letters, 2015-08, Vol.25 (15), p.2958-2962

2015

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis

Bioorganic & medicinal chemistry letters, 2017-08, Vol.27 (16), p.3939-3943

2017

Link zum Volltext

Verfügbarkeit prüfen

Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2015-08, Vol.25 (15), p.2958-2962

2015

Link zum Volltext

Verfügbarkeit prüfen

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties

Bioorganic & medicinal chemistry letters, 2014-03, Vol.24 (6), p.1615-1620

2014

Link zum Volltext

Verfügbarkeit prüfen

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh sub(2) antagonists with favorable pharmacokinetic and drug-like properties

Bioorganic & medicinal chemistry letters, 2014-03, Vol.24 (6), p.1615-1620

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Synthesis of the Oxygenated Pactamycin Core

CXCR2 receptor antagonists: a medicinal chemistry perspective

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

Substituted dibenzo[c, h]cinnolines: Topoisomerase I-targeting anticancer agents

Chemoselective Peptide Modification via Photocatalytic Tryptophan β‑Position Conjugation

Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region

3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists

Synthesis and structure–activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

CXCR2 modulators: a patent review (2009 - 2013)

Identification of Oxidation Products of (−)-Epigallocatechin Gallate and (−)-Epigallocatechin with H2O2

Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2‑Substituted Benzamide Zinc Binding Group

A new synthesis of 3,4-disubstituted 1,2,5-thiadiazoles

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV‑1 Protein for Clearance

Synthesis of HDAC Inhibitor Libraries via Microscale Workflow

Discovery of novel BTK inhibitors with carboxylic acids

Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis

Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists

Discovery of 8‑Amino-imidazo[1,5‑a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh sub(2) antagonists with favorable pharmacokinetic and drug-like properties

Suchergebnisse filtern